Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Advances in pharmacokinetics and pharmacodynamics of PD-1/PD-L1 inhibitors
Ting Yan, Yu Lun, Dangang Shangguan, et al.
International Immunopharmacology (2022) Vol. 115, pp. 109638-109638
Open Access | Times Cited: 21

Showing 21 citing articles:

PD-1 and PD-L1: architects of immune symphony and immunotherapy breakthroughs in cancer treatment
Adil Parvez, Furqan Choudhary, Priyal Mudgal, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 67
Current Status in Rechallenge of Immunotherapy
Han Hu, Ke Wang, Rong Jia, et al.
International Journal of Biological Sciences (2023) Vol. 19, Iss. 8, pp. 2428-2442
Open Access | Times Cited: 24
Spatiotemporal metabolomic approaches to the cancer-immunity panorama: a methodological perspective
Yang Xiao, Yongsheng Li, Huakan Zhao
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 7
The Interaction Between Vasculogenic Mimicry and the Immune System: Mechanistic Insights and Dual Exploration in Cancer Therapy
Shutong Liu, Mei Kang, Yuqing Ren, et al.
Cell Proliferation (2025)
Open Access
Efficacy and safety of first-line PD-1/PD-L1 inhibitor in combination with CTLA-4 inhibitor in the treatment of patients with advanced non-small cell lung cancer: a systemic review and meta-analysis
Huimin Zhao, Shanshan Huang, Jianyu Wu, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Immuno-oncological Challenges and Chemoresistance in Veterinary Medicine: Probiotics as a New Strategic Tool
Muhammad Nisar, Tingdong Yan, Yi Cai, et al.
Probiotics and Antimicrobial Proteins (2025)
Closed Access
A Comparative Molecular Dynamics Study of Food-Derived Compounds as PD-L1 Inhibitors: Insights Across Six Flavonoid Subgroups
Dejun Jiang, Hyuk-Ku Kwon, Oh Wook Kwon, et al.
Molecules (2025) Vol. 30, Iss. 4, pp. 907-907
Open Access
A phase I, open-label, multicentre, first-in-human study to evaluate safety, pharmacokinetics and efficacy of AMG 404, a PD-1 inhibitor, in patients with advanced solid tumours
Timothy Price, Iwona Ługowska, Sant P. Chawla, et al.
BMJ Open (2025) Vol. 15, Iss. 5, pp. e088578-e088578
Open Access
N6-methyladenosine reader protein IGF2BP1 suppresses CD8 + T cells-mediated tumor cytotoxicity and apoptosis in colon cancer
Yao Peng, Zhili Zhang, Gong‐Li Yang, et al.
APOPTOSIS (2023) Vol. 29, Iss. 3-4, pp. 331-343
Closed Access | Times Cited: 10
Fc–Fc interactions and immune inhibitory effects of IgG4: implications for anti-PD-1 immunotherapies
Weifeng Zhang, Xueling Chen, Xingxing Chen, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 6, pp. e009034-e009034
Open Access | Times Cited: 3
Application of newly developed and validated lc-ms/ms method for pharmacokinetic study of adagrasib and pembrolizumab simultaneously in rat plasma
Kamma Harsha Sri, Panchumarthy Ravisankar, Sathish Kumar Konidala, et al.
Journal of Chromatography B (2024) Vol. 1241, pp. 124171-124171
Closed Access | Times Cited: 2
Systemic treatment options for non-small cell lung cancer after failure of previous immune checkpoint inhibitors: a bayesian network meta-analysis based on randomized controlled trials
Kang Wang, Zhenxue Fu, Guanxing Sun, et al.
BMC Immunology (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 2
Clinical Characteristics, Management and Prognostic Factors of Immune Checkpoint Inhibitor-Associated Pneumonia in Chinese Cancer Patients
Jinlan Li, Shanshan Chen, Ting Yan, et al.
Journal of College of Physicians And Surgeons Pakistan (2024) Vol. 34, Iss. 3, pp. 302-307
Open Access | Times Cited: 1
Efficacy and Safety of Anti–Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Antibodies Plus Chemotherapy as First-Line Treatment for NSCLC in the People’s Republic of China: a Systematic Review and Meta-Analysis
Qian Chen, Kai Ma, Lin Zhang, et al.
JTO Clinical and Research Reports (2024) Vol. 5, Iss. 6, pp. 100678-100678
Open Access | Times Cited: 1
Sequential treatment of anti-PD-L1 therapy prior to anti-VEGFR2 therapy contributes to more significant clinical benefits in non-small cell lung cancer
Qiao-xin Lin, Wen-Wen Song, Wenxia Xie, et al.
Neoplasia (2024) Vol. 59, pp. 101077-101077
Open Access | Times Cited: 1
Advances of M1 macrophages-derived extracellular vesicles in tumor therapy
Houli Liu, Zhaorong Ouyang, Siyu Li
Biomedicine & Pharmacotherapy (2024) Vol. 181, pp. 117735-117735
Open Access | Times Cited: 1
Therapeutic drug monitoring of immune checkpoint inhibitors: based on their pharmacokinetic properties and biomarkers
Dongxue Liu, Linlin Hu, Hua Shao
Cancer Chemotherapy and Pharmacology (2023) Vol. 92, Iss. 3, pp. 165-179
Closed Access | Times Cited: 2
Reversing T Cell Exhaustion by Converting Membrane PD-1 to Its Soluble form in Jurkat Cells; Applying The CRISPR/Cas9 Exon Skipping Strategy.
Zeinab Yousefi-Najafabadi, Zohreh Mehmandoostli, Yazdan Asgari, et al.
PubMed (2023) Vol. 25, Iss. 9, pp. 633-644
Closed Access | Times Cited: 2
Sequential Treatment of Anti-Pd-L1 Therapy Prior to Anti-Vegfr2 Therapy Contributes to More Significant Clinical Benefits in Non-Small Cell Lung Cancer
Qiao-xin Lin, Wen-Wen Song, Wenxia Xie, et al.
(2024)
Closed Access
New benzophenone analogs from Nigrospora sphaerica and their inhibitory activity against PD-1/PD-L1 interactions
Qi-Xuan Kuang, Yuqing Huang, Yan-qiu Ruan, et al.
Bioorganic Chemistry (2024) Vol. 153, pp. 107899-107899
Closed Access
Emerging strategies in cancer immunotherapy: Expanding horizons and future perspectives
Olisaemeka Zikora Akunne, Ogochukwu Emilia Anulugwo, Michelle Azu
International Journal of Molecular and Immuno Oncology (2024) Vol. 9, pp. 77-99
Closed Access
Effect of AGEs-RAGE system on the efficacy of PD-1 inhibitors in the treatment of driver-gene mutation negative advanced non-squamous non-small cell lung cancer
Xiangying Li, Guan Wang, Xiuye Sun, et al.
Cellular and Molecular Biology (2023) Vol. 69, Iss. 14, pp. 155-160
Open Access | Times Cited: 1
Page 1

Scroll to top